David A. Cory's most recent trade in Eiger BioPharmaceuticals Inc was a trade of 48,750 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 29, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eiger BioPharmaceuticals Inc | David A. Cory | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | David A. Cory | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 281,000 | 281,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | David A. Cory | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 47,000 | 117,846 (0%) | 0% | 0 | Common Stock |